source
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and moreGSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncologySTAT · 1mo ago↗ source
- Dexcom RCT suggests CGM benefits for broad diabetes populationIn this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.STAT · 1mo ago↗ source
- GSK boosts cancer pipeline with $11B Nuvalent buyoutThe British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.BioPharma Dive · 1mo ago↗ source